Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet
Purpose To review and update the European LeukemiaNet (ELN) recommendations for the
management of chronic myeloid leukemia with imatinib and second-generation tyrosine …
management of chronic myeloid leukemia with imatinib and second-generation tyrosine …
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on …
S Soverini, A Hochhaus, FE Nicolini… - Blood, The Journal …, 2011 - ashpublications.org
Abstract Mutations in the Bcr-Abl kinase domain may cause, or contribute to, resistance to
tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia patients. Recommendations …
tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia patients. Recommendations …
Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia
A Quintás-Cardama, HM Kantarjian… - Cancer control, 2009 - journals.sagepub.com
Background Although the vast majority of patients with chronic myeloid leukemia (CML)
respond to the tyrosine kinase inhibitor (TKI) imatinib mesylate, resistance might occur de …
respond to the tyrosine kinase inhibitor (TKI) imatinib mesylate, resistance might occur de …
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
MC Müller, JE Cortes, DW Kim… - Blood, The Journal …, 2009 - ashpublications.org
Dasatinib is a BCR-ABL inhibitor with 325-fold higher potency than imatinib against
unmutated BCR-ABL in vitro. Imatinib failure is commonly caused by BCR-ABL mutations …
unmutated BCR-ABL in vitro. Imatinib failure is commonly caused by BCR-ABL mutations …
Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status
M Schmidt, J Rinke, V Schäfer, S Schnittger… - Leukemia, 2014 - nature.com
To study clonal evolution in chronic myeloid leukemia (CML), we searched for BCR-ABL-
independent gene mutations in both Philadelphia chromosome (Ph)-negative and Ph …
independent gene mutations in both Philadelphia chromosome (Ph)-negative and Ph …
Unraveling the complexity of tyrosine kinase inhibitor–resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain
S Soverini, C De Benedittis… - Blood, The Journal …, 2013 - ashpublications.org
In chronic myeloid leukemia and Philadelphia chromosome–positive acute lymphoblastic
leukemia, tyrosine kinase inhibitor (TKI) therapy may select for drug-resistant BCR-ABL …
leukemia, tyrosine kinase inhibitor (TKI) therapy may select for drug-resistant BCR-ABL …
Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options
EJ Jabbour, JE Cortes, HM Kantarjian - Clinical Lymphoma Myeloma and …, 2013 - Elsevier
The development of tyrosine kinase inhibitors (TKIs) has led to extended lifespans for many
patients with chronic myelogenous leukemia (CML). However, 20% to 30% of patients fail to …
patients with chronic myelogenous leukemia (CML). However, 20% to 30% of patients fail to …
The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international …
A Kohlmann, HU Klein, S Weissmann, S Bresolin… - Leukemia, 2011 - nature.com
Massively parallel pyrosequencing allows sensitive deep sequencing to detect molecular
aberrations. Thus far, data are limited on the technical performance in a clinical diagnostic …
aberrations. Thus far, data are limited on the technical performance in a clinical diagnostic …
Sensitive Detection of BCR-ABL1 Mutations in Patients With Chronic Myeloid Leukemia After Imatinib Resistance Is Predictive of Outcome During Subsequent …
WT Parker, RM Lawrence, M Ho, DL Irwin… - Journal of Clinical …, 2011 - ascopubs.org
Purpose BCR-ABL1 mutation analysis is recommended to facilitate selection of appropriate
therapy for patients with chronic myeloid leukemia after treatment with imatinib has failed …
therapy for patients with chronic myeloid leukemia after treatment with imatinib has failed …
Monitoring treatment of chronic myeloid leukemia
1Department of Hematology-Oncology" L. and A. Seràgnoli" University of Bologna, Bologna;
2Onco-Hematology Unit, University of Naples Federico II and CEINGE, Biotecnologie …
2Onco-Hematology Unit, University of Naples Federico II and CEINGE, Biotecnologie …